Clara Rodríguez Fernández, Author at Labiotech.eu - Page 31 of 62

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

Heather Barnett Slime Mold

News and Trends 16 Sep 2017

How Does it Feel Like to be a Slime Mold in Berlin?

Bioartist Heather Barnett explores the amusing world of a microorganism that can navigate its way around cities much like a human would do. Physarum polycephalum, commonly known as slime mold, is a fascinating microorganism. This yellow single-celled being has no brain or nervous system, but it can play piano and write Hebrew. It can also […]

September 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

numab intarcia autoimmune disease

News and Trends 15 Sep 2017

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […]

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

bayer ginkgo bioworks plant microbiome biotech

News and Trends 15 Sep 2017

Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A

Bayer and Ginkgo Bioworks are launching a new company that will develop new technologies for sustainable agriculture by engineering the plant microbiome. With the microbiome already gaining traction in the therapeutics field, Bayer has decided to take it to agriculture. In partnership with US synthetic biology upstart Ginkgo Bioworks, the German giant is creating a new […]

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

amylon therapeutics proqr rna therapy

More News! 14 Sep 2017

New Dutch Spin Out will Treat Stroke with RNA Therapy

ProQR has spun out Amylon Therapeutics, a company that will treat central nervous system disorders with a lead candidate based on RNA technology. Amylon Therapeutics, a brand new spin-out from RNA company ProQR, has announced its first seed investment round. The funds, of an undisclosed amount, will help the new company kick off the development of its drug candidates. Based in Leiden, Amylon […]

September 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

SkinGun RenovaCare Stem Cell Gun

Interview 14 Sep 2017

Inside the Lab Building a Stem Cell Gun to Heal Skin

Thomas Bold, CEO of RenovaCare, shares the story of how his team developed a futuristic stem cell gun to heal burns and wounds. Inside the building that used to be home to Berlin’s Tempelhof airport, whose abandoned runways are regularly visited by picnickers and skaters, an American and a German company are collaborating on the […]

September 14, 2017 - 6 minutesmins - By Clara Rodríguez Fernández

alligator bioscience cancer cd137

News and Trends 13 Sep 2017

A Swedish-Spanish Team Takes on a New Immuno-Oncology Target

Alligator Bioscience will collaborate with the University of Navarra, Spain, to study the potential of CD137 as a target for new cancer immunotherapies. Alligator Bioscience, based in Lund, Sweden, has teamed up with Prof. Ignacio Melero at the Center for Applied Medical Research (CIMA) at the University of Navarra to study the biological effects of activating […]

September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

4sc resminostat biliary cancer

News and Trends 13 Sep 2017

Epigenetics Drug Proves Effective in Phase I for Lethal Cancer

4SC’s partner Yakult Honsha has presented positive results at ESMO 2017 for the epigenetics drug resminostat in a Phase I trial run in Japan. The histone deacetylase (HDAC) inhibitor resminostat has shown to induce tumor shrinkage or disease stabilization in all patients with biliary tract cancer in a Phase I trial. The goal was to determine […]

September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Sophia Genetics artificial intelligence fundraising

News and Trends 13 Sep 2017

Series D Boost will Bring Artificial Intelligence to Diagnostics Worldwide

Sophia Genetics has raised $30M (€25M) in Series D that will be directed to growing and improving its artificial intelligence platform for genetic diagnostics. The Swiss company Sophia Genetics has announced today a new round of funding, led by Balderton Capital, and joined by 360º Capital Partners and existing investors Invoke Capital and Alychlo. The […]

September 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

HIV therapy infographic

Infographics 13 Sep 2017

The 10 Most Innovative HIV Treatments to Defeat AIDS

This infographic gathers 10 of the best HIV treatments in Europe’s pipeline that will help doctors worldwide fight against AIDS better than ever before. With an estimated 36.7 million people living with HIV worldwide, the search for an effective treatment that can overcome the fast evolution of the virus is rapidly gaining traction. In Europe, […]

September 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández

deinove bpifrance antibiotics

News and Trends 12 Sep 2017

France Invests €15M in Developing a New Generation of Antibiotics

Deinove has received funding from Bpifrance to work on the discovery of the next generation of antibiotics to fight antibiotic-resistant pathogens. The Investments for the Future Program, operated by the French public investment bank Bpifrance, has granted €14.6M to the Antibiotics against Resistant Infectious Germs (AGIR) project, carried out by the Deinove group in collaboration […]

September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

onxeo livatag nanoparticle cancer

News and Trends 12 Sep 2017

French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III

Onxeo has announced Phase III results for its nanoparticle chemotherapy Livatag, which failed to improve the outcome for patients with hepatocellular carcinoma compared to other available treatments. The stock of the French oncology specialist Onxeo was halved this morning when it revealed the results of a Phase III trial with its candidate Livatag that failed to […]

September 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

DNA Script Sylvain Gariel COO

News and Trends 12 Sep 2017

French Startup Raises €11M in Series A to Reinvent DNA Synthesis

DNA Script has gathered the support of key international investors to take a new, faster DNA synthesis technology closer to the market. In a Series A round led by Illumina Ventures and joined by Merck Ventures and existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners, the young French startup DNA Script has raised a total […]

September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT